September 9, 2022 – ASCO: Amgen’s Stomach Cancer Drug, Nabbed in Five Prime Buyouts, Extends Patients’ Lives in Phase 2

Amgen battled other biopharma suitors for Five Prime Therapeutics early this year, emerging victorious in March with a $1.9 billion deal to snap up the cancer-focused biotech. Now, the company is painting a fuller picture for bemarituzumab, the crown jewel of the buyout, showing the treatment helped patients with advanced stomach cancer live longer.